Aurobindo Pharma Re-Appoints M. R. Kumar as Independent Director for Five Years
Aurobindo Pharma Ltd 路 Change in Management 路 05 Nov 2026, 2:08 am
Aurobindo Pharma Re-Appoints M. R. Kumar as Independent Director for Five Years Aurobindo Pharma's Board approved the re-appointment of Mr. Mangalam Ramasubramanian Kumar as Non-Executive and Independent Director for a second five-year term effective 1st Apr'27, upon the completion of his initial term on 31st Mar'27. The re-appointment is subject to shareholder approval via special resolution through postal ballot. Mr. Kumar, a former Chairman of LIC of India and current Non-Executive Chairman of Bank of India, is not liable to retire by rotation and has no relationships with any director or Key Managerial Personnel of the company.
Original exchange filing (PDF)
More announcements from Aurobindo Pharma Ltd
- Intimation of classification of US FDA inspection at Lannet Company LLC, a wholly owned subsidiary of Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company. 路 12 Nov 2026
- Submission of Earning Call Transcript for Q2FY27. 路 11 Nov 2026
- Unit-2 of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company received Establishment Inspection Report from US FDA with classification as "Voluntary Action Indicated". 路 11 Nov 2026
- Intimation of investors / analysts meet to be held on 17.11.2026. 路 09 Nov 2026
- Intimation of investor / analysts meet to be held on 16.09.2026. 路 09 Nov 2026
- Submission of Financial results for the Quarter and Half year ended September 30, 2026. 路 05 Nov 2026
- Transfer of ownership of Auro Pharma LLC, Russia from Auroactive Pharma Private Limited to Auropharm Overseas Limited, Wholly Owned subsidiaries of the Company. 路 05 Nov 2026
- Approved the proposal of Merger of two wholly owned subsidiaries of the Company. 路 05 Nov 2026
